

Fonkozumib Injection

Bortezomib 3.5 mg/ml

Lyophilized powder for injection IV

1. What Fonkozumib Injection Is Used For

Fonkozumib is an anti-cancer medication classified as a proteasome inhibitor. It works by disrupting the protein degradation process in cells, which induces apoptosis (cell death) in cancer cells.

Indications:

- **Multiple Myeloma (MM):**
 - As a single agent or in combination with other therapies for the treatment of multiple myeloma in patients who have received at least one prior therapy.
 - **Mantle Cell Lymphoma (MCL):**
 - For patients with mantle cell lymphoma who have received at least one prior therapy.
-

2. Before Fonkozumib Injection Is Administered to You

Fonkozumib Injection Should Not Be Used If:

- You are allergic to bortezomib, boron, or any other ingredients in the formulation.
- You have severe liver impairment unless otherwise specified by your doctor.
- You are pregnant or breastfeeding.

Special Care Should Be Taken with Fonkozumib Injection:

- **Peripheral Neuropathy:**
 - Patients with existing neuropathy should be closely monitored as the drug may exacerbate nerve damage.
- **Hematological Disorders:**
 - The drug can suppress bone marrow, leading to low levels of white blood cells, red blood cells, and platelets.
- **Infections:**
 - Use with caution in patients with ongoing or recurring infections.
- **Liver and Kidney Function:**
 - Dose adjustments may be necessary for patients with impaired hepatic or renal function.
- **Heart Problems:**

- Inform your doctor of any existing heart conditions, as the medication can cause or worsen heart failure or arrhythmias.

Pregnancy and Breastfeeding:

- **Pregnancy:**
 - Fonkozmib may harm an unborn baby. Effective contraception must be used during treatment and for at least three months after the last dose.
- **Breastfeeding:**
 - Do not breastfeed during treatment as it may harm the infant.

3. How Fonkozmib Injection Is Administered to You

Method and Routes of Administration:

- Administered under the supervision of a healthcare professional experienced in cancer therapy.
- Can be administered as:
 - Intravenous injection (into a vein).
 - Subcutaneous injection (under the skin).

Dosage:

- **Multiple Myeloma and Mantle Cell Lymphoma:**

- Recommended starting dose: 1.3 mg/m² body surface area twice weekly for two weeks, followed by a 10-day rest period (21-day cycle).

Pre-Medication:

- Patients may receive prophylactic medications to manage nausea, vomiting, and peripheral neuropathy.

Preparation and Administration:

- Healthcare providers dilute and prepare the injection before administration.
- For intravenous use, a syringe or infusion system with a 0.22-micron filter is recommended.

4. Possible Side Effects

Like all medications, Fonkozmib can cause side effects. Not everyone will experience these.

Common Side Effects:

- **Blood Disorders:**
 - Neutropenia (low white blood cell count)
 - Thrombocytopenia (low platelet count)

- Anemia (low red blood cell count)
- **Gastrointestinal Disorders:**
 - Nausea, vomiting, diarrhea, and constipation
- **Nervous System Disorders:**
 - Peripheral neuropathy (numbness or tingling in extremities)
- **Musculoskeletal Disorders:**
 - Muscle weakness and joint pain
- **General Disorders:**
 - Fatigue, fever, and weakness

Serious Side Effects (Seek Medical Attention):

- Severe allergic reactions (rash, difficulty breathing, swelling of the face or throat)
- Severe infections (fever, chills, persistent cough)
- Symptoms of heart problems (chest pain, rapid heartbeat)
- Severe neuropathy or unusual bruising/bleeding

5. Storing Fonkozomib Injection

- **Storage Temperature:**

- Store vials at 2°C to 8°C (36°F to 46°F).
- **Protection:**
 - Keep in the original packaging to protect from light.
- **Shelf Life:**
 - Refer to the expiration date printed on the packaging.
- **After Reconstitution:**
 - Use immediately. If not used immediately, store refrigerated and use within eight hours.

6. Further Information

Composition:

- Each vial contains:
 - **Bortezomib:** 3.5 mg (lyophilized powder for reconstitution).

Other Ingredients:

- Mannitol

Presentation:

- Supplied in single-use vials containing 3.5 mg of Bortezomib.

Manufacturer:



Imported & marketed by:



Head Office: Office No. 4, First Floor, Ghousia Plaza, Jinnah Avenue, Blue Area, Islamabad, Pakistan. **Phone No.** +92 51 2274145-46 **Email:** info@amgomed.org